SPRY Stock Risk & Deep Value Analysis

ARS Pharmaceuticals, Inc.

DVR Score

8.3

out of 10

Hidden Gem

The Bottom Line on SPRY

We analyzed ARS Pharmaceuticals, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran SPRY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 28, 2025•Run Fresh Analysis →

📈SPRY Performance Overview3yr weekly

📊

Unlock SPRY Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

SPRY Deep Value Analysis

SPRY targets a massive anaphylaxis market with neffy, a potential first-in-class needle-free epinephrine spray, offering significant patient benefits and market disruption. Strong cash runway post-PIPE financing and a resilient leadership team navigating regulatory setbacks demonstrate execution capacity. The upcoming PDUFA date (July 2024) is a critical, binary catalyst; approval would unlock substantial market share and multi-bagger potential. However, regulatory failure (reiterated by prior CRL) poses a showstopping risk, making this a high-risk, high-reward bet for 10x growth.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on SPRY

Create a free account to set price alerts and get notified on Telegram when SPRY hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for ARS Pharmaceuticals, Inc. (SPRY)?

As of September 28, 2025, ARS Pharmaceuticals, Inc. has a DVR Score of 8.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the SPRY DVR analysis updated?

Our AI-powered analysis of ARS Pharmaceuticals, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 28, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.